@article{95420,
  keywords = {Parasitology, Infectious Diseases, General Medicine, praziquantel (PZQ)},
  author = {Enabulele EE and Platt RN and Adeyemi E and Agbosua E and Aisien MS and Ajakaye OG and Ali MU and Amaechi EC and Atalabi TE and Auta T and Awosolu OB and Dagona AG and Edo-Taiwo O and Ejikeugwu CE and Igbeneghu C and Njom VS and Orji MN and Oyinloye FO and Ozemoka HJ and Ugah UI and Anderson TJ},
  title = {Urogenital schistosomiasis in Nigeria post receipt of the largest single praziquantel donation in Africa},
  abstract = {Schistosomiasis control efforts in Nigeria received a boost in 2016 when Merck Group made the largest single donation of praziquantel to an African country. We examined urine samples from 2,023 school age children from 15 locations in 10 states and an Internally Displaced Person's (IDP) camp in Nigeria. We recorded an overall Schistosoma haematobium prevalence of 10.4% in the 10 states that ranged between 6 – 37%, while prevalence in the IDP camp was 2.9%. The highest infection prevalence (37%) recorded was from the population in Wasai Dam area in Minjibir (Kano State), while five locations had no positive urine samples. We observed heavy intensity of infection (≥ 50 eggs/10 ml urine) in 87.9% of infected samples and co-occurrence of the eggs of S. haematobium and S. mansoni in urine for two participants. The overall prevalence we recorded is slightly above the national average (9.5%) reported in 2015. Our findings indicate that despite the ongoing administration of praziquantel in Nigeria, urogenital schistosomiasis is still prevalent with heavy intensity of infection. Large-scale epidemiological monitoring is required to monitor the efficacy of schistosomiasis control in Nigeria.},
  year = {2021},
  journal = {Acta Tropica},
  volume = {219},
  pages = {105916},
  publisher = {Elsevier BV},
  issn = {0001-706X},
  doi = {10.1016/j.actatropica.2021.105916},
  language = {eng},
}